Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452006 | 1.00 | CA12 (0.47) | CA12CA1CA9KAT6AKMT2A | |
| SCHEMBL3403454 | 0.84 | KAT6A (0.60) | CA12CA1CA9KAT6AKMT2A | |
| SCHEMBL30216106 | 0.84 | KAT6A (0.60) | CA12CA1CA9KAT6AKMT2A | |
| SCHEMBL467281 | 0.84 | KMT2A (0.56) | KMT2AMEN1NPC1RECQLRAB9A | |
| SCHEMBL23158879 | 0.83 | KAT6A (0.50) | CA12CA1CA9KAT6ARXFP1 | |
| SCHEMBL4672586 | 0.82 | NPC1 (0.50) | CA12CA1CA9KAT6AKMT2A | |
| SCHEMBL12599766 | 0.82 | CA12 (0.47) | CA12CA1CA9KAT6AKMT2A | |
| SCHEMBL22804523 | 0.82 | CA12 (0.47) | CA12CA1CA9KAT6ANPC1 | |
| SCHEMBL20932800 | 0.82 | MEN1 (0.47) | CA12CA1CA9KAT6AKMT2A | |
| SCHEMBL23484531 | 0.82 | CA12 (0.47) | CA12CA1CA9KAT6AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109020820-B | Preparation method of 6-bromo-2-aminonaphthalene | 杭州惠诺医药科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-109020820-B | Preparation method of 6-bromo-2-aminonaphthalene | 杭州惠诺医药科技有限公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3022185-B1 | PESTICIDE COMPOUNDS | BASF SE (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9497970-B2 | Pesticide compounds | BASF SE (DE) | 2016-11-22 | — | — | US | disclosed |
| US-20160157491-A1 | Pesticide Compounds | BASF SE (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-3022185-A1 | PESTICIDE COMPOUNDS | BASF SE (DE) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007682-A1 | PESTICIDE COMPOUNDS | BASF SE (DE) | 2015-01-22 | — | — | WO | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2011075607-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075439-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010096302-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-7498068-B2 | Liquid-crystal aligning agent, liquid-crystal alignment film comprising the same, and liquid-crystal element | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7498068-B2 | Liquid-crystal aligning agent, liquid-crystal alignment film comprising the same, and liquid-crystal element | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20070224370-A1 | Liquid-Crystal Aligning Agent, Liquid-Crystal Alignment Film Comprising the Same, and Liquid-Crystal Element | NISSAN CHEMICALS INDUSTRIES, LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070224370-A1 | Liquid-Crystal Aligning Agent, Liquid-Crystal Alignment Film Comprising the Same, and Liquid-Crystal Element | NISSAN CHEMICALS INDUSTRIES, LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CA12 3169/4885CA1 4434/4885CA9 3974/4885 |
| US-20160157491-A1 | Pesticide Compounds | C1R, C1S, CBR3 | CA12 3117/4885CA1 1110/4885CA9 844/4885 |
| US-20110152246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, IRF3 | CA12 4538/4885CA1 4777/4885CA9 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.